Innovative therapies are often based on new treatment algorithms and thus require different processes than conventional therapies. When new therapies are introduced, neither the provider nor the healthcare provider can foresee exactly whether and how the healthcare provider's human and financial resource requirements will change due to the application of new therapies. A process cost analysis helps to ensure planning security.

A process cost analysis shows providers and users which medical, nursing, technical and administrative staff are involved in which activities in the treatment process and to what extent. The need for human, material and financial resources can thus be quantified over the entire treatment process and also compared with other therapies. "Medically comparable therapies do not always cause comparable costs. Transparent therapy costs are the prerequisite for an efficient use of resources."

Time is a limited resource in healthcare, so we use a software-based approach (Ibexx©). To minimise the time needed by the healthcare provider, we first create a process model based on standard operating procedures (SOPs), publications and our experience. The model is then validated and adjusted with the people involved. The costs are then calculated by our team using anonymised controlling data.

Our software Ibexx© enables a graphical representation and the use of standardised names of individual services and processes to enable a comparison of different treatments and/or settings (e.g. university hospital vs. acute hospital). Thus, the software saves time in validating and adapting the model with involved persons.

Every year, pharmaceutical and medical technology companies bring a variety of new therapies and technologies to market. In 2022 alone, 89 medicines were approved in the European Union, 41 of which had a new active ingredient. Many of these new therapies require new organisational, technical and medical processes for their application. We support healthcare providers in assessing the impact of new therapies on their own financial and human resources in advance.

·You need a longer-term outlook on new therapies for your resource planning. - you do not have the resources for market monitoring and analysis - You cannot estimate the extent of the impact of new therapies and technologies on your resources depending on your patients and over time.

- an innovative therapy with new treatment processes comes onto the market - it is unclear how the new technology or therapy will concretely affect one's own processes and thus resources depending on increasing patient numbers - different therapies with comparable therapeutic benefit are to be compared holistically at process cost level in order to identify those therapies that can be used most efficiently from a personnel, organisational and financial point of view

Market access aims to ensure primary market access by negotiating prices and reimbursement restrictions (limitatio) with payers. How often the therapy is then used is a question of Therapy Access and, in the case of innovative therapies with new treatment processes, requires a deeper understanding of the processes, costs and revenues at the healthcare provider. This understanding has a significant influence on how quickly and to what extent a new therapy is used and brings the expected benefits to patients.

Pharmacoeconomic models are developed in parallel with randomised controlled trials. The outcome of the model is often measured in costs per QALY (quality-adjusted life years). Pharmacoeconomic models serve as a basis for price negotiations with payers within the framework of market access. Process cost analyses are primarily not models, they represent the resource and cost reality of healthcare providers and, from the perspective of the healthcare providers, enable the optimal use of resources depending on the success of the treatment.

For providers of innovative medical therapies, it is a significant advantage if their own therapy can positively influence the processes, resource requirements and costs as well as the achievable revenues at the service provider. With our software-based method IBEXX, we can identify and quantify precisely these advantages.

If innovative therapies are introduced to the market, the application of which causes a change in the workflows and processes of the service provider, the resource requirements can already be estimated during the pre-launch phase. Red flags (e.g. missing resources or additional therapy costs) can thus be identified at an early stage.

A Red Flag Analysis is used when: - an innovative therapy with new treatment procedures comes onto the market - possible resource bottlenecks at the healthcare provider that could limit the use of the therapy need to be quickly identified and assessed - an already established therapy is not used as frequently as expected for no obvious reason - New therapies from competitors come onto the market, which influence processes at the healthcare provider and can thus have an indirect effect on the provider's own therapy.